

ITEMS RECOMMENDED BETWEEN ORDINARY MEETINGS (JULY 2021 - NOVEMBER 2021)

SPONSOR, TYPE OF SUBMISSION	DRUG TYPE AND USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME	
<p>MELATONIN</p> <p>Tablet 1 mg Tablet 5 mg</p> <p>Slenyto®</p> <p>Aspen Pharmacare Australia Pty Ltd Early</p> <p>Matters outstanding (New listing)</p>	<p>Insomnia</p>	<p>To request an Authority Required (Telephone) listing for the treatment of insomnia in patients between the ages of 2 and 18 with Smith-Magenis syndrome.</p>	<p>Recommended</p>	<p>The PBAC recommended the listing of melatonin for the treatment of insomnia in patients with Smith-Magenis Syndrome. The PBAC's recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of melatonin in this population would be acceptable at the price proposed by the sponsor.</p>
<p>RIBAVIRIN</p> <p>Tablet 200 mg</p> <p>Ibavyr®</p> <p>Clinect Pty Ltd</p> <p>Other Business (New strength)</p>	<p>Chronic hepatitis C infection</p>	<p>To request the listing of ribavirin (Ibavyr®) 200 mg tablets (100 pack) on the PBS under the same conditions as the currently listed ribavirin 400 mg and 600 mg tablets.</p>	<p>Recommended</p>	<p>The PBAC recommended the listing of ribavirin (Ibavyr®) 200 mg tablets (100 pack) on the PBS under the same conditions as the currently listed ribavirin 400 mg and 600 mg tablets but with a maximum quantity of 200 tablets and a maximum of two repeats. This will provide one months' supply per dispensing at the maximum dose and will be enough to complete the treatment course for the available PBS listed hepatitis C regimens.</p>
<p>UPADACITINIB</p> <p>Tablet 15 mg Tablet 30 mg</p> <p>Rinvoq®</p> <p>Abbvie Pty Ltd</p> <p>Matters outstanding (Change to listing)</p>	<p>Severe atopic dermatitis</p>	<p>To request a General Schedule, Authority Required (Telephone) listing for the treatment of severe atopic dermatitis.</p>	<p>Recommended</p>	<p>The PBAC recommended the listing of upadacitinib for severe atopic dermatitis. The PBAC's recommendation for listing was based on, among other matters, its assessment, that the cost-effectiveness of upadacitinib 15 mg or 30 mg would be acceptable if it were cost-minimised against dupilumab.</p>